Cenicriviroc for the treatment of COVID-19: first interim results of a randomised, placebo-controlled, investigator-initiated, double-blind phase II trial
Kurth et al., Journal of Global Antimicrobial Resistance, doi:10.1016/j.jgar.2022.12.004
https://c19early.org/kurth.html